Puma Biotechnology | PBYI - Sales Revenues


Puma Biotechnology reported $80.54M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Exelixis USD 610.8M 12.14M Mar/2026
Gilead Sciences USD 7.93B 130M Dec/2025
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.27B 240M Mar/2026
MacroGenics USD 41.23M 31.61M Dec/2025
Moderna USD 389M 289M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Takeda JPY 1.19T 80B Dec/2025
TG Therapeutics USD 194.8M 2.23M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026